Intellectual Property Protection and Formulary Coverage: Evidence From Ontario
Speaker: Paul Grootendorst
Date/Time: September 12, 2014
During the last 25 years, the Canadian government has strengthened Intellectual Property (IP) protections afforded to innovative pharmaceutical drugs. By delaying generic entry, these policy changes have presumably increased revenues accruing to brand firms. Revenues accruing to brand drugs, however, depend critically on the length of exclusivity on the formularies of the major drug plans. It is possible that, in the face of stronger IP protections for brand drugs, drug plans have become more restrictive in their coverage of new brand drugs. To test this, we assess the period of formulary exclusivity for the brand drugs approved for use in Canada over the last 35 years. We focus on the formulary of the Ontario Drug Benefit (ODB) plan, the largest plan in Canada. We focus on the fraction of new drugs approved each year that were listed on the ODB formulary, the time between drug approval and formulary listing, and the time between formulary listing and the formulary listing of the first interchangeable generic drug. Results will be presented at the seminar.
Paul Grootendorst is an Associate Professor and Director of the Division of Social and Administrative Pharmacy in the Leslie Dan Faculty of Pharmacy at the University of Toronto. He is also a Faculty Associate of the Canadian Centre for Health Economics. His research interests are on the economic aspects of the pharmaceutical industry, including drug development; pharmaceuticals use, insurance and reimbursement; and interactions between innovative (brand) and generic drug firms. He also has an interest in methods for program evaluation using observational data.